Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
McKinsey
Medtronic
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,555,544

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,555,544 protect, and when does it expire?

Patent 6,555,544 protects INVEGA SUSTENNA and is included in one NDA.

Protection for INVEGA SUSTENNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-five patent family members in thirty-four countries.

Summary for Patent: 6,555,544
Title: Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters
Abstract:The present invention is concerned with a pharmaceutical composition suitable as a depot formulation for administration via intramuscular or subcutaneous injection, comprising: (1) as an active ingredient a therapeutically effective amount of a 9-hydroxy-risperidone fatty acid ester or a salt, or a stereoisomer or a stereoisomeric mixture thereof in submicron form and (2) a pharmaceutically acceptable carrier; wherein the pharmaceutically acceptable carrier is water and the active ingredient is suspended therein: and with a process of preparing such a composition. The invention further concerns such a pharmaceutical composition for use as a medicament in the treatment of psychosis, schizophrenia, schizoaffective disorders, non-schizophrenic psychoses, behavioural disturbances associated with neurodegenerative disorders, e.g. in dementia, behavioural disturbances in mental retardation and autism, Tourette's syndrome, bipolar mania, depression, anxiety.
Inventor(s): Fran.cedilla.ois; Marc Karel Jozef (Kapellen, BE), Dries; Willy Maria Albert Carlo (Merksplas, BE), Basstanie; Esther Dina Guido (Zandhoven, BE)
Assignee: Janssen Pharmaceutica, N.V. (BE)
Application Number:09/530,687
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Use;

Drugs Protected by US Patent 6,555,544

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-001 Jul 31, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-002 Jul 31, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-003 Jul 31, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-004 Jul 31, 2009 RX Yes Yes   Start Trial   Start Trial   Start Trial
Janssen Pharms INVEGA SUSTENNA paliperidone palmitate SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR 022264-005 Jul 31, 2009 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,555,544

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
97203568Nov 17, 1997
PCT Information
PCT FiledNovember 10, 1998PCT Application Number:PCT/EP98/07321
PCT Publication Date:May 27, 1999PCT Publication Number: WO99/25354

International Family Members for US Patent 6,555,544

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1228   Start Trial
Argentina 016686   Start Trial
Austria 239480   Start Trial
Australia 2049199   Start Trial
Australia 745540   Start Trial
Bulgaria 104422   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Mallinckrodt
AstraZeneca
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.